# G0S2

## Overview
The G0S2 gene encodes the G0/G1 switch 2 protein, a small regulatory protein involved in lipid metabolism and cell cycle regulation. This protein is characterized by its alpha-helical structure and is known for its role as an inhibitor of adipose triglyceride lipase (ATGL), thereby influencing lipid storage and energy homeostasis (Heckmann2013The; Moran2021Biophysical). G0/G1 switch 2 is expressed in various tissues, including adipose tissue and liver, and its expression is modulated by nutritional and hormonal signals (Heckmann2013The). Beyond its metabolic functions, G0/G1 switch 2 interacts with the anti-apoptotic protein Bcl-2, promoting apoptosis, and is implicated in the regulation of cell cycle progression, particularly in maintaining hematopoietic stem cells in a quiescent state (Heckmann2013The). Clinically, the gene is significant in cancer biology, where it often acts as a tumor suppressor, and in metabolic disorders, where its deletion can lead to resistance to obesity and insulin resistance (Mohan2019OR293; ElAssaad2014Deletion).

## Structure
The G0S2 protein is a small protein with a molecular weight of approximately 11.4 kDa, consisting of 104 amino acid residues (Moran2021Biophysical). Its primary structure is encoded by the G0S2 gene. The protein is characterized by the presence of two alpha helices separated by a hydrophobic sequence and a beta sheet, although the complete atomic resolution structure has not been fully determined (Moran2021Biophysical). 

G0S2 exhibits dominant alpha-helical characteristics, as indicated by preliminary NMR spectroscopy measurements (Moran2021Biophysical). The protein contains a hydrophobic region near the C-terminus, which is responsible for binding and inhibiting adipose triglyceride lipase (ATGL) by competing with CGI-58, an activator of ATGL (Moran2021Biophysical). This hydrophobic region contributes to protein aggregation, posing challenges for structural studies (Moran2021Biophysical).

The protein may exist in a multimeric state, suggesting a potential quaternary structure that stabilizes it within the cell (Moran2021Biophysical). However, specific details on the quaternary structure are not provided. Parts of G0S2 are highly flexible, indicating intrinsic disorder (Moran2021Biophysical).

## Function
The G0S2 gene encodes a protein that plays a significant role in lipid metabolism and energy homeostasis in healthy human cells. It primarily functions by inhibiting adipose triglyceride lipase (ATGL), a key enzyme in lipolysis, thereby reducing the breakdown of triglycerides into free fatty acids and promoting fat storage (Heckmann2013The). This inhibition is crucial for maintaining lipid droplet size in adipocytes and regulating energy balance (Yim2016G0S2).

G0S2 is expressed in various tissues, including adipose tissue and liver, and its expression is modulated by nutritional and hormonal signals. For instance, its expression decreases in adipose tissue during fasting but increases in the liver, suggesting a role in managing free fatty acid levels and preventing cytotoxic effects (Heckmann2013The). G0S2 is also involved in regulating cell cycle progression, particularly in the transition from the G0 to G1 phase, and may help maintain hematopoietic stem cells in a quiescent state (Heckmann2013The).

In addition to its metabolic functions, G0S2 interacts with the anti-apoptotic protein Bcl-2, promoting apoptosis in certain cell types, which indicates its involvement in cell growth and apoptosis regulation (Heckmann2013The). The gene's expression is also linked to immune function, with increased levels observed in autoimmune conditions (Yim2016G0S2).

## Clinical Significance
The G0S2 gene has significant clinical implications in various diseases, particularly in cancer and metabolic disorders. In adrenocortical carcinoma (ACC), G0S2 is frequently hypermethylated, leading to its silencing. This epigenetic alteration is a hallmark of a specific aggressive molecular subtype of ACC, known as CIMP-high carcinomas, which are associated with rapid recurrence and poor prognosis. G0S2 hypermethylation serves as a prognostic marker, predicting shorter disease-free and overall survival in ACC patients (Mohan2019OR293).

In cancer biology, G0S2 acts as a tumor suppressor. It is often epigenetically silenced in various cancers, including head and neck cancer, non-small cell lung cancer, and breast cancer. Reexpression of G0S2 can inhibit cancer cell proliferation and induce apoptosis, suggesting its potential as a therapeutic target (Welch2009Identification; Yim2016G0S2).

In metabolic disorders, G0S2 is involved in lipid metabolism. Its deletion in mice leads to resistance to high-fat-diet-induced obesity and insulin resistance, indicating its role in regulating fat metabolism. G0S2 acts as a lipase inhibitor, and its absence enhances lipolysis and energy expenditure (ElAssaad2014Deletion).

## Interactions
The G0S2 protein is known to interact with several proteins, influencing various cellular processes. One significant interaction is with the antiapoptotic protein Bcl-2. G0S2 binds directly to Bcl-2, antagonizing its function by preventing the formation of protective Bcl-2/Bax heterodimers, which are crucial for Bcl-2's antiapoptotic activity. This interaction promotes apoptosis and is essential for the proapoptotic function of G0S2 (Welch2009Identification).

G0S2 also interacts with adipose triglyceride lipase (ATGL), inhibiting its triglyceride hydrolase activity. This interaction is facilitated by the hydrophobic domain of G0S2 and the patatin-like domain of ATGL, playing a significant role in regulating lipolysis in adipocytes (Heckmann2013The; Zhang2017G0S2:).

In the context of chronic myeloid leukemia (CML), G0S2 interacts with nucleolin in the cytosol of K562 cells. This interaction sequesters nucleolin away from the nucleus, inhibiting its pro-proliferative functions and reducing cell proliferation, suggesting a potential tumor suppressor role for G0S2 in leukemia cells (Yamada2014G0S2).


## References


[1. (Yim2016G0S2) Christina Y. Yim, David J. Sekula, Mary P. Hever-Jardine, Xi Liu, Joshua M. Warzecha, Janice Tam, Sarah J. Freemantle, Ethan Dmitrovsky, and Michael J. Spinella. G0s2 suppresses oncogenic transformation by repressing a myc-regulated transcriptional program. Cancer Research, 76(5):1204–1213, February 2016. URL: http://dx.doi.org/10.1158/0008-5472.CAN-15-2265, doi:10.1158/0008-5472.can-15-2265. This article has 56 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.CAN-15-2265)

[2. (Moran2021Biophysical) Michael W. Moran, Elizabeth P. Ramirez, James D. Zook, Alicia M. Saarinen, Bobby Baravati, Matthew R. Goode, Vasiliki Laloudakis, Emily K. Kaschner, Tien L. Olson, Felicia M. Craciunescu, Debra T. Hansen, Jun Liu, and Petra Fromme. Biophysical characterization and a roadmap towards the nmr solution structure of g0s2, a key enzyme in non-alcoholic fatty liver disease. PLOS ONE, 16(7):e0249164, July 2021. URL: http://dx.doi.org/10.1371/journal.pone.0249164, doi:10.1371/journal.pone.0249164. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0249164)

[3. (Mohan2019OR293) Dipika Mohan, Antonio Lerario, Tobias Else, Madson Almeida, Michelle Vinco, Juilee Rege, Beatriz Mariani, Maria Zerbini, Berenice Mendonca, Ana Claudia Latronico, Suely Marie, William Rainey, Thomas Giordano, Maria Fragoso, and Gary Hammer. Or29-3 targeted assessment of g0s2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Journal of the Endocrine Society, April 2019. URL: http://dx.doi.org/10.1210/js.2019-or29-3, doi:10.1210/js.2019-or29-3. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1210/js.2019-or29-3)

[4. (Welch2009Identification) Christian Welch, Manas K. Santra, Wissal El-Assaad, Xiaochun Zhu, Wade E. Huber, Richard A. Keys, Jose G. Teodoro, and Michael R. Green. Identification of a protein, g0s2, that lacks bcl-2 homology domains and interacts with and antagonizes bcl-2. Cancer Research, 69(17):6782–6789, August 2009. URL: http://dx.doi.org/10.1158/0008-5472.can-09-0128, doi:10.1158/0008-5472.can-09-0128. This article has 108 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/0008-5472.can-09-0128)

[5. (ElAssaad2014Deletion) Wissal El-Assaad, Karim El-Kouhen, Amro H. Mohammad, Jieyi Yang, Masahiro Morita, Isabelle Gamache, Orval Mamer, Daina Avizonis, Nicole Hermance, Sander Kersten, Michel L. Tremblay, Michelle A. Kelliher, and Jose G. Teodoro. Deletion of the gene encoding g0/g1 switch protein 2 (g0s2) alleviates high-fat-diet-induced weight gain and insulin resistance, and promotes browning of white adipose tissue in mice. Diabetologia, 58(1):149–157, November 2014. URL: http://dx.doi.org/10.1007/s00125-014-3429-z, doi:10.1007/s00125-014-3429-z. This article has 35 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00125-014-3429-z)

[6. (Heckmann2013The) Bradlee L. Heckmann, Xiaodong Zhang, Xitao Xie, and Jun Liu. The g0/g1 switch gene 2 (g0s2): regulating metabolism and beyond. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1831(2):276–281, February 2013. URL: http://dx.doi.org/10.1016/j.bbalip.2012.09.016, doi:10.1016/j.bbalip.2012.09.016. This article has 88 citations.](https://doi.org/10.1016/j.bbalip.2012.09.016)

[7. (Yamada2014G0S2) Takeshi Yamada, Chun Shik Park, Ye Shen, Karen R. Rabin, and H. Daniel Lacorazza. G0s2 inhibits the proliferation of k562 cells by interacting with nucleolin in the cytosol. Leukemia Research, 38(2):210–217, February 2014. URL: http://dx.doi.org/10.1016/j.leukres.2013.10.006, doi:10.1016/j.leukres.2013.10.006. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.leukres.2013.10.006)

[8. (Zhang2017G0S2:) Xiaodong Zhang, Bradlee L. Heckmann, Latoya E. Campbell, and Jun Liu. G0s2: a small giant controller of lipolysis and adipose-liver fatty acid flux. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1862(10):1146–1154, October 2017. URL: http://dx.doi.org/10.1016/j.bbalip.2017.06.007, doi:10.1016/j.bbalip.2017.06.007. This article has 66 citations.](https://doi.org/10.1016/j.bbalip.2017.06.007)